PULM vs. ASLN, BFRI, AIMD, IBIO, HILS, VCNX, TENX, PCSA, KTTA, and SHPH
Should you be buying Pulmatrix stock or one of its competitors? The main competitors of Pulmatrix include ASLAN Pharmaceuticals (ASLN), Biofrontera (BFRI), Ainos (AIMD), iBio (IBIO), Hillstream BioPharma (HILS), Vaccinex (VCNX), Tenax Therapeutics (TENX), Processa Pharmaceuticals (PCSA), Pasithea Therapeutics (KTTA), and Shuttle Pharmaceuticals (SHPH). These companies are all part of the "pharmaceutical preparations" industry.
Pulmatrix (NASDAQ:PULM) and ASLAN Pharmaceuticals (NASDAQ:ASLN) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their community ranking, institutional ownership, valuation, earnings, profitability, analyst recommendations, dividends, media sentiment and risk.
Pulmatrix has higher earnings, but lower revenue than ASLAN Pharmaceuticals. Pulmatrix is trading at a lower price-to-earnings ratio than ASLAN Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
11.8% of Pulmatrix shares are held by institutional investors. Comparatively, 58.8% of ASLAN Pharmaceuticals shares are held by institutional investors. 3.6% of Pulmatrix shares are held by insiders. Comparatively, 4.7% of ASLAN Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
In the previous week, Pulmatrix had 1 more articles in the media than ASLAN Pharmaceuticals. MarketBeat recorded 2 mentions for Pulmatrix and 1 mentions for ASLAN Pharmaceuticals. Pulmatrix's average media sentiment score of 0.00 equaled ASLAN Pharmaceuticals'average media sentiment score.
Pulmatrix has a beta of 0.9, suggesting that its share price is 10% less volatile than the S&P 500. Comparatively, ASLAN Pharmaceuticals has a beta of 1.52, suggesting that its share price is 52% more volatile than the S&P 500.
ASLAN Pharmaceuticals has a net margin of 0.00% compared to Pulmatrix's net margin of -75.73%. Pulmatrix's return on equity of -44.05% beat ASLAN Pharmaceuticals' return on equity.
ASLAN Pharmaceuticals received 4 more outperform votes than Pulmatrix when rated by MarketBeat users. Likewise, 63.49% of users gave ASLAN Pharmaceuticals an outperform vote while only 51.99% of users gave Pulmatrix an outperform vote.
Pulmatrix presently has a consensus target price of $10.00, indicating a potential upside of 410.20%. ASLAN Pharmaceuticals has a consensus target price of $11.33, indicating a potential upside of 2,411.82%. Given ASLAN Pharmaceuticals' higher possible upside, analysts clearly believe ASLAN Pharmaceuticals is more favorable than Pulmatrix.
Summary
ASLAN Pharmaceuticals beats Pulmatrix on 10 of the 16 factors compared between the two stocks.
Get Pulmatrix News Delivered to You Automatically
Sign up to receive the latest news and ratings for PULM and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding PULM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Pulmatrix Competitors List
Related Companies and Tools
